Display Single Record

FOI Request

Disclosure ID
FOI/01704
Request Date
June 2, 2016
Subject
Prostate, Liver And Gastro Cancer
Description

Q1
a) Within your trust how many unique patients with Advanced Prostate Cancer have been treated in the past 12 months?
b) How many patients with Advanced Prostate Cancer have received:
Abiraterone (Zytiga)
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Enzalutamide (Xtandi)
Radium-223 (Xofigo)
Bicalutamide (Casodex)

Advanced prostate cancer is cancer that has spread outside the prostate to other parts of the body such as the bones

Q2
a) How many unique patients with Hepatocellular Carcinoma have been treated in the past 12 months?
b) How many patients with Hepatocellular Carcinoma have received:
Bevacizumab (Avastin)
Everolimus (Afinitor)
Lapatinib (Tyverb)
Sorafenib (Nexavar)
Sunitinib (Sutent)

Q3
a) How many unique patients with Gastrointestinal Stromal Tumours have been treated in the past 12 months?

b) How many patients with Gastrointestinal Stromal Tumours have received;
Dasatinib (Sprycel)
Imatininb (Glivec)
Nilotinib (Tasigna)
Pazopanib (Votrient)
Regorafenib (Stivarga)
Sorafenib (Nexavar)
Sunitinib (Sutent)

Response
    1. Malignant neoplasm of prostate:
      540 patients.
      Please note, this figure is for all unique patients with prostate cancer. Our coding system does not distinguish between prostate cancer and advanced prostate cancer. To provide further information would require a manual trawl of patient records which would exceed 18 hours. Further information is therefore exempt under Section 12(1) of the FOI Act.
    2. Our pharmacy system does not store the clinical indication. As such, we are only able to provide the number of patients who have received the requested medication, and not indication for which they were used.
      Abiraterone: 53
      Cabazitaxel: 8
      Enzalutamide: 99
      Bicalutamide: 282
    1. Liver cell carcinoma (includes hepatocellular carcinoma):
      15 patients.
    2. Our pharmacy system does not store the clinical indication. As such, we are only able to provide the number of patients who have received the requested medication, and not indication for which they were used.
      Bevacizumab: 19
      Everolimus: 7
      Lapatinib: 1
      Sorafenib: 7
      Sunitinib: 6
    1. Neoplasm of uncertain or unknown behaviour of digestive organ, unspecified (this covers GIST, but is not exclusive and can therefore include additional tumours):
      10 patients.
    2. Our pharmacy system does not store the clinical indication. As such, we are only able to provide the number of patients who have received the requested medication, and not indication for which they were used.
      Dasatinib: 7
      Nilotinib: 11
      Pazopanib:19
      Regorafenib: 1
      Sorafenib: 7
      Sunitinib: 6
Attachment 1
Attachment 2
Attachment 3
Attachment 4
Attachment 5
Attachment 6
Attachment 7
Attachment 8
Attachment 9